Stroncek David F, Berger Carolina, Cheever Martin A, Childs Richard W, Dudley Mark E, Flynn Peter, Gattinoni Luca, Heath James R, Kalos Michael, Marincola Francesco M, Miller Jeffrey S, Mostoslavsky Gustavo, Powell Daniel J, Rao Mahendra, Restifo Nicholas P, Rosenberg Steven A, O'Shea John, Melief Cornelis J M
Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA.
J Transl Med. 2012 Mar 15;10:48. doi: 10.1186/1479-5876-10-48.
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.
一场关于癌症细胞疗法的峰会讨论并展示了与过继性细胞疗法用于黑色素瘤及其他癌症相关的进展。该峰会表明这一领域正在迅速发展。传统的细胞疗法，如肿瘤浸润淋巴细胞（TIL），正变得更有效且更易获得。基因疗法正成为过继性细胞疗法中的一项重要工具。淋巴细胞经过改造后可表达高亲和力T细胞受体（TCR）、嵌合抗体-T细胞受体（CAR）和细胞因子。在临床前模型中已表明，具有更多初始和干细胞样特征的T细胞亚群比未筛选的群体更有效，现在有可能对T细胞进行重编程并产生具有干细胞特征的T细胞。未来，可以设想将T细胞的过继转移与针对同源抗原的特异性疫苗接种相结合，以进一步提高这些疗法的有效性。
